Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02930226 · ClinicalTrials.gov registry record · Phase 1
Ascending Doses of Autologous FDP vs FFP
A Phase 1 study of Freeze Dried Plasma in Healthy Volunteers, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT02930226 is a Phase 1 study of Freeze Dried Plasma in Healthy Volunteers that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02930226, a Phase 1 study of Freeze Dried Plasma in Healthy Volunteers, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Assess the safety of single infusions with RePlas FDP product at increasing fixed doses
Conditions Studied
Interventions
- BIOLOGICAL Fresh Frozen Plasma (FFP)
- BIOLOGICAL Autologous Freeze Dried Plasma (FDP)
Study Locations (1)
Ohio
- Hoxworth Blood Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-02-13 |
| Est. Completion | 2018-08-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02930226
The ClinicalTrials.gov registry entry for NCT02930226 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is U.S. Army Medical Research and Development Command, which has 77 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Freeze Dried Plasma in Healthy Volunteers appearing as the primary indexed condition, and to 2 interventions - of which Fresh Frozen Plasma (FFP) is the first listed.
NCT02930226 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT02930226 about?
NCT02930226 is a clinical study titled "Ascending Doses of Autologous FDP vs FFP". Assess the safety of single infusions with RePlas FDP product at increasing fixed doses
What is the current status of trial NCT02930226?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2017-02-13. Estimated completion is 2018-08-02.
What conditions does trial NCT02930226 study?
This clinical trial studies the following conditions: Freeze Dried Plasma in Healthy Volunteers.
What interventions are being tested in trial NCT02930226?
The interventions under investigation include: Fresh Frozen Plasma (FFP) (BIOLOGICAL), Autologous Freeze Dried Plasma (FDP) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02930226?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02930226 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.